Are β-sheet breaker peptides dissolving the therapeutic problem of Alzheimer's disease?

Journal of Neural Transmission, Supplement

Volumn , Issue 62, 2002, Pages 293-301

  Permanne, B ^a   Adessi, C ^a   Fraga, S ^a   Frossard, M J ^a   Saborio, G P ^a   Soto, C ^a,b  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

^b NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; AMYLOID; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; BETA SHEET; CONFERENCE PAPER; DEGENERATIVE DISEASE; GENE TARGETING; HUMAN; METABOLIC REGULATION; NERVE DEGENERATION; PAIRED HELICAL FILAMENT; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; STEM CELL; AGED; AMINO ACID SEQUENCE; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; MOLECULAR GENETICS; PROTEIN SECONDARY STRUCTURE; REVIEW;

AGED; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID; AMYLOID BETA-PROTEIN; DRUG DESIGN; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, SECONDARY;

EID: 0036050867     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6139-5_27     Document Type: Conference Paper

References (38)

1. Annaert W, Cupers P, Saftig P, De Strooper B (2000) Presenilin function in APP processing. Ann NY Acad Sci 920: 158-164
2. Citron M (2000) Secretases as targets for the treatment of Alzheimer's disease. Mol Med Today 6: 392-397
3. Duff K (1999) Curing amyloidosis: will it work in humans? Trends Neurosci 22: 485-486
4. Emilien G, Beyreuther K, Masters CL, Maloteaux JM (2000) Prospects for pharmacological intervention in Alzheimer disease. Arch Neurol 57: 454-459
5. Fortini ME (2001) Notch and presenilin: a proteolytic mechanism emerges. Curr Opin Cell Biol 13: 627-634
6. Fraser PE, Yang DS, Yu G, Levesque L, Nishimura M, Arawaka S, Serpell LC, Rogaeva E, George-Hyslop P (2000) Presenilin structure, function and role in Alzheimer disease. Biochim Biophys Acta 1502: 1-15
7. Hardy J, Duff K, Hardy KG, Perez-Tur J, Hutton M (1998) Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat Neurosci 1: 355-358
8. Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, Tang MX, Mayeux R (2001) Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol 49: 808-810
9. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, George-Hyslop P, Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982
10. Kelly JW (1996) Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 6: 11-17
11. Knopman D, Morris JC (1998) An update on primary drug therapies for Alzheimer's disease. Arch Neurol 54: 1406-1409
12. Lee VMY (2001) Aβ immunization: moving Aβ peptide from brain to blood. Proc Natl Acad Sci USA 98: 8931-8932
13. Mann DM (1989) Cerebral amyloidosis, ageing and Alzheimer's disease; a contribution from studies on Down's syndrome. Neurobiol Aging 10: 397-399
14. McKeon-O'Malley C, Saunders AJ, Bush AI, Tanzi RE (1998) Potential therapeutic targets for Alzheimer's disease. Emerging Therapeutic Targets 2: 157-179
15. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985
16. Price DL, Tanzi RE, Borchelt DR, Sisodia SS (1998) Alzheimer's disease: genetic studies and transgenic models. Annu Rev Genet 32: 461-493
17. Sabbagh MN, Galasko D, Thal LJ (1997) β-amyloid and treatment opportunities for Alzheimer's disease. Alzheimer's Disease Review 3: 1-19
18. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177
19. Selkoe DJ (1991) The molecular pathology of Alzheimer's disease. Neuron 6: 487-498
20. Selkoe DJ (2000) Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 924: 17-25
21. Selkoe DJ, Wolfe MS (2000) In search of gamma-secretase: presenilin at the cutting edge. Proc Natl Acad Sci USA 97: 5690-5692
22. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, McCormack R, Wolfert R, Selkoe DJ, Lieberburg I, Schenk DB (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359: 325-327
23. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD, McKay DM, Tintner R, Frangione B, Younkin SG (1992) Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258: 126-129
24. Sigurdsson EM, Permanne B, Soto C, Wisniewski T, Frangione B (2000) In vivo reversal of amyloid-β lesions in rat brain. J Neuropathol Exp Neurol 59: 11-17
25. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T (2001) Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 159: 439-447
26. Soto C (1999a) Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol Med Today 5: 343-350
27. Soto C (1999b) β-amyloid disrupting drugs: potential in the treatment of Alzheimer's disease. CNS Drugs 12: 347-356
28. Soto C (2001) Protein misfolding and disease; protein refolding and therapy. FEBS Lett 498: 204-207
29. Soto C, Branes MC, Alvarez J, Inestrosa NC (1994) Structural determinants of the Alzheimer's amyloid beta-peptide. J Neurochem 63: 1191-1198
30. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B (1998) β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nature Med 4: 822-826
31. St George-Hyslop PH, Westaway D (1999) Antibody clears senile plaques. Nature 400: 116-117
32. Teplow DB (1998) Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid 5: 121-142
33. Terry RD (1994) Neuropathological changes in Alzheimer disease. Prog Brain Res 101: 383-390
34. Van Leuven F (2000) Single and multiple transgenic mice as models for Alzheimer's disease. Prog Neurobiol 61: 305-312
35. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741
36. Wolfe MS (2001a) Presenilin and gamma-secretase: structure meets function. J Neurochem 76: 1615-1620
37. Wolfe MS (2001b) Secretase targets for Alzheimer's disease: identification and therapeutic potential. J Med Chem 44: 2039-2060
38. Younkin SG (1995) Evidence that Aβ 42 is the real culprit in Alzheimer's disease. Ann Neurol 37: 287-288